28.1 C
New York
Thursday, July 3, 2025

Tag: guarantee

Westhaven Closes Non-Brokered Private Placement with Eric Sprott and Earthlabs, for Gross Proceeds of $3.16 Million

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

DBI Investor News: If You Have Suffered Losses in Designer Brands Inc. (NYSE: DBI), You Are Encouraged to Contact The Rosen Law Firm About...

NEW YORK, July 03, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Designer Brands Inc. (NYSE: DBI) resulting from allegations that Designer Brands may have issued materially misleading business information to the investing public.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OLO, MRC, GNTY on Behalf of Shareholders

NEW YORK, July 03, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

REE Automotive Receives Nasdaq Minimum Bid Price Notification

TEL AVIV, Israel, July 03, 2025 (GLOBE NEWSWIRE) -- REE Automotive Ltd. (“REE” or the “Company”) (Nasdaq: REE), an automotive technology company that develops software-defined vehicle (SDV) technology solutions, today reported that the Company received a letter (the “Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is currently not in compliance with Nasdaq Rule 5450(a)(1). In particular, the Letter stated that the Company’s closing bid price for its Class A ordinary shares (the “Ordinary Shares”) has been below $1.00 per share for the last 30 consecutive business days beginning on May 15, 2025 through June 27, 2025.

ROSEN, LEADING INVESTOR COUNSEL, Encourages Petco Health and Wellness Company, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – WOOF

NEW YORK, July 03, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Petco Health and Wellness Company, Inc. (NASDAQ: WOOF) between January 14, 2021 and June 5, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 29, 2025.

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Compass Diversified

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Compass To Contact Him Directly To Discuss Their Options If...

KORE joins the Russell Microcap® Index

ATLANTA, July 3, 2025 /PRNewswire/ -- KORE Group Holdings, Inc. (NYSE: KORE), the global pure-play IoT hyperscaler and provider of Connectivity, Solutions, and Analytics, has been...

Gate Launches xStocks Trading Section, Bridging Crypto Finance and Global Capital Markets

PANAMA CITY, July 03, 2025 (GLOBE NEWSWIRE) -- In July 2025, Gate, a global leading digital asset trading platform, officially launched its xStocks trading section, covering both spot and futures markets. The initial listings include 8 popular tokenized stocks, such as COINX, NVDAX, CRCLX, AAPLX, METAX, HOODX, TSLAX, and GOOGLX, enabling global users to trade tokenized stocks directly with crypto assets like USDT. Gate Alpha has also rolled out support for xStocks, listing MSTRx, CRCLx, SPYx, NVDAx, TSLAx, and AAPLx, further expanding users’ access to on-chain assets and strategic trading options.

Christina Lake Cannabis Announces Delay in Filing its 2024 Annual Financial Statements

VANCOUVER, British Columbia, July 03, 2025 (GLOBE NEWSWIRE) -- Christina Lake Cannabis Corp. ("CLC" or the "Company") (CSE: CLC) announced today that it will not be filing its annual financial statements, accompanying management's discussion and analysis and related chief executive officer ("CEO") and chief financial officer ("CFO") certifications for the financial year ended February 28, 2025 (collectively, the "Annual Filings"), within the period prescribed for the filing of such documents under Parts 4, 5 and 6 of National Instrument 51-102 Continuous Disclosure Obligations and pursuant to National Instrument 52-109 Certification of Disclosure in Issuers' Annual and Interim Filings, namely within 120 days of year-end, being June 30, 2025 (the "Filing Deadline").

APPLOVIN ALERT: Bragar Eagel & Squire, P.C. is Investigating AppLovin Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against AppLovin Corporation (NASDAQ:APP) on behalf of long-term stockholders following a class action complaint that was filed against AppLovin on March 5, 2025 with a Class Period from May 10, 2023 to March 26, 2025.. Our investigation concerns whether the board of directors of AppLovin have breached their fiduciary duties to the company.

RUFFOLO, HOOPER & ASSOCIATES, MD, PA ALERT: Bragar Eagel & Squire, P.C. is Investigating Ruffolo, Hooper & Associates, MD, PA on Behalf of Ruffolo,...

NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized consumer rights law firm, is investigating potential claims against Ruffolo, Hooper & Associates, MD, PA (“Ruffolo, Hooper & Associates, MD, PA” or the “Company”) on behalf of Ruffolo, Hooper & Associates, MD, PA consumers. Our investigation concerns whether Ruffolo, Hooper & Associates, MD, PA has violated consumer protection laws and/or engaged in other unlawful business practices.

Dizal’s ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

ZEGFROVY is the only approved targeted oral treatment for NSCLC with EGFR exon20insApproval follows the U.S. FDA's Priority Review and is supported by the pivotal WU-KONG1 Part B study, in which...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsGuarantee